Posts by Hyon Choi, MD, DrPH
-
Study Positions SGLT2 Inhibitors as Gout Treatment
A Massachusetts General Hospital research team has found that SGLT2 inhibitor therapy reduces gout flares and lowers the risk of myocardial infarction in patients with diabetes.
-
Higher Hydroxychloroquine Dose Progressively Increases Incidence of Retinopathy
April M. Jorge, MD, Hyon K. Choi, MD, Yuqing Zhang, ScD, and colleagues conducted a large "real-world" study of the incidence of hydroxychloroquine retinopathy under contemporary dosing and surveillance standards, finding a dose-related risk of 8.6% after 15 years. 90% of cases were mild or moderate.
-
Allopurinol Treatment-to-Target Does Not Increase Mortality Risk in Patients With Comorbid Gout, CKD
Yuqing Zhang, DSc, Hyon K. Choi, MD, and colleagues found that allopurinol use does not increase the five-year risk of death in patients with gout and concurrent chronic kidney disease, either overall or when analyses were limited to patients who achieved the target serum urate level or required dose escalation.
-
Review: Cardiometabolic–Renal Comorbidities in Gout
Hyon K. Choi, MD, Chio Yokose, MD, MS, and Natalie McCormick, PhD, of the Division of Rheumatology, Allergy and Immunology, suggest pharmacologic agents that can both lower urate levels in patients with gout and treat common cardiometabolic-renal comorbidities of the disease.
-
Multicenter Study: Rituximab Promising for Interstitial Pneumonia with Autoimmune Features
In a retrospective study, researchers at Massachusetts General Hospital and University of Chicago Medicine found that the majority of patients with interstitial pneumonia with autoimmune features treated with rituximab had clinical improvement or stability, with few adverse events.
-
Pilot Study: DASH Diet Reduces Serum Urate in Patients with Gout
Hyon K. Choi, MD, of the Division of Rheumatology, Allergy and Immunology, and colleagues report preliminary evidence that a dietitian-directed, DASH-patterned behavioral intervention lowers serum urate in gout patients not on urate-lowering drugs.
-
COVID-19 Patients with Rheumatic and Musculoskeletal Diseases at Substantial Risk of Poor Outcomes
Clinicians in the Division of Rheumatology, Allergy and Immunology found that for patients with rheumatic and musculoskeletal diseases who develop COVID-19, the risks of death and other severe outcomes have declined since early in the pandemic but remain considerable.
-
Clinical Epidemiology Program Advances Rheumatology Care
Massachusetts General Hospital's Clinical Epidemiology Program utilizes multidisciplinary collaborations, big data and omics sciences to advance rheumatology and COVID-19 care.
Biography
Dr. Hyon Choi received his rheumatology fellowship training at Massachusetts General Hospital and Harvard Medical School, and his master's and doctorate degrees in epidemiology from Harvard University. Dr. Choi has been a leading clinical rheumatologist and investigator with a primary focus on gout, rheumatoid arthritis, and psoriatic arthritis throughout his academic career, as reflected by his funding (National Institutes of Health [NIH] and industry), publications (over 200, including >60 gout-related peer-reviewed papers including those published in NEJM, JAMA, Lancet, Nat Genet, Ann Int Med, BMJ, Arch Int Med, Am J Med, Ann Rheum Dis, A&R), and reviewer activities for top journals and the NIH. The significance of Dr. Choi's contributions has been widely accepted by the field, and his findings have been referenced by many articles as well as by the recent guidelines from the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR, 2012). His clinical and epidemiologic research has provided state-of-the-art evidence to inform the gout field, which is needed to move its guidelines from expert-consensus to an evidence-based approach.
Rheumatology, Allergy and Immunology
The Division of Rheumatology, Allergy and Immunology at Massachusetts General Hospital provides leading-edge treatment and transformative care to patients with rheumatic disease and autoimmune conditions.